日前，全球知名指数公司MSCI宣布了2025年11月份指数审核结果，"国内食用油龙头"金龙鱼等20只股 票被剔除，此次调整将于11月24日收盘后正式生效。 2020年10月，金龙鱼在深交所上市，发行价格25.70元/股。上市当年，金龙鱼实现营收1949.22亿元，同 比增长14.16%，但之后金龙鱼似乎"游"不动了。 2020年至2024年，金龙鱼的归母净利润逐年下滑，分别为60.01亿元、41.32亿元、30.11亿元、28.48亿 元、25.02亿元。与此同时，公司的毛利率一路走低后略微回暖，分别为11.01%、8.18%、5.68%、 4.83%、5.35%。 2025年前三季度，公司业绩大幅回暖，实现营业收入1842.70亿元，同比增长5.02%；归母净利润为 27.49亿元，同比增长92.06%；扣非归母净利润为20.17亿元，同比增长745.88%。 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入(千元) | 68.588.056 | 3 ...

（原标题：港股概念追踪 | MSCI中国指数调整将生效 关注个股尾盘异动 外资持续加码中国优质资产(附概念股)） 智通财经APP获悉，全球知名指数公司MSCI此前宣布了2025年11月份指数审核结果，此次调整将于2025年11月24日收盘后正式生效。在MSCI的 系列指数中，涉及A股的包括MSCI中国指数、MSCI中国A股在岸指数以及MSCI中国全股票指数。其中最值得关注的是MSCI中国指数。MSCI中 国指数被嵌套进MSCI新兴市场指数，因此股票进入MSCI中国指数，便意味着进入了MSCI全球标准指数系列，从而获得被动资金跟踪。 MSCI中国指数本次新增26只标的，包括多只资源股，以及半导体、高端制造等科技类公司。新增个股包括9只港股：紫金黄金国际(02259)、广发 证券(01776)、赣锋锂业(01772)、中国有色矿业(01258)、中国黄金国际(02099)、荣昌生物(09995)、东风集团(00489)、优必选(09880)、晶泰控股 (02228)。以及华虹公司、生益电子、英维克、长盈精密、江波龙、中材科技等17只A股。 同时，MSCI中国指数剔除了20只中国股票，其中包括4只港股：北控水务集团 ...

重点关注 MSCI中国指数调整将生效 全球知名指数公司MSCI此前宣布了2025年11月份指数审核结果，此次调整将于11月24日收盘后正式生效。 本次调整中，MSCI中国指数新纳入26只中国股票，剔除20只，具体变动标的如下： | 新增 | 剔除 | | --- | --- | | 中国黄金国际 | 中直股份 | | 中国有色矿业 | 北控水务集团 | | 千里科技 | 伯特利 | | 东风集团股份 | 中国光大银行 | | 赣锋锂业 | 华润医药 | | 广发证券 | 东阿阿胶 | | 东阳光 | 广电运通 | | 长川科技 | 海格通信 | | 华虹公司 | 海澜之家 | | V. II+ 相 相 | 化工H-Am | MSCI中国指数被嵌套进MSCI新兴市场指数，因此股票进入MSCI中国指数，便意味着进入了MSCI全球标准指数系列，从 而获得被动资金跟踪。随着MSCI多个指数成份股调整，相关的指数基金也将随之调仓，新纳入的企业将得到更多的资金配 置；而被剔除的企业将会被相关指数基金被动卖出。资金流向上，根据指数调整的历史经验来看，被动型资金为了尽可能 地减少对于指数的追踪误差，通常会选在最后一天调仓，因 ...

Core Viewpoint - Haier Home has been removed from the MSCI China Index, which may impact its market liquidity and capital attention due to its recent performance decline [1]. Group 1: MSCI Index Changes - MSCI announced the results of its index review for November 2025, with 26 Chinese companies being added and 20 removed, including Haier Home [1]. - The removal from the MSCI index is significant as it typically indicates a loss of international investment interest [1]. Group 2: Financial Performance - In the third quarter of 2025, Haier Home reported a revenue of 15.599 billion yuan, a year-on-year increase of 2.23%, and a net profit of 1.816 billion yuan, up 3.86% [1]. - The main brand, Haier Home, experienced a revenue decline of 3.99% to 10.849 billion yuan, marking a continuous decline since the second half of 2024 [1]. Group 3: Business Model and Market Position - Haier Home relies heavily on the ODM (Original Design Manufacturer) model, outsourcing most production processes to suppliers, which reduces inventory risk but limits control over design and development [3]. - The company faces challenges of product homogeneity and low repurchase rates due to its large-scale operations under the ODM model, necessitating a transformation to enhance brand, product, channel, and service [3]. - The brand struggles to attract younger consumers, which is critical for maintaining market relevance and growth [2].

Core Viewpoint - MSCI announced changes to the MSCI China Index, adding 26 stocks and removing 20, effective after market close on November 24 [1] Group 1: Changes in Index Constituents - Nine new stocks listed in Hong Kong include China Gold International (02099.HK), Zijin Mining International (02259.HK), UBTECH Robotics (09880.HK), Ganfeng Lithium (01772.HK), Dongfeng Motor Group (00489.HK), Crystal International (02228.HK), China Nonferrous Mining (01258.HK), Rongchang Biopharma (09995.HK), and GF Securities (01776.HK) [1] - Four stocks removed from the index include China Everbright Bank (06818.HK), Beijing Enterprises Water Group (00371.HK), AVIC Trust (00696.HK), and China Resources Pharmaceutical (03320.HK) [1] Group 2: Impact on Stock Weights - The adjustment will affect the free float factors of 19 companies and the number of shares for 142 companies, leading to changes in index weightings [1] - New entrants like China Gold International, Zijin Mining International, UBTECH Robotics, and Ganfeng Lithium will see their weights increase, while Tencent (00700.HK), Alibaba-W (09988.HK), Kuaishou-W (01024.HK), and China Everbright Bank will experience the largest declines in weight [2] Group 3: Predicted Fund Flows - Expected inflows for stocks with increased weights include: - China Gold International (02099.HK): +0.129%, inflow of $187 million - Zijin Mining International (02259.HK): +0.12%, inflow of $173 million - UBTECH Robotics (09880.HK): +0.116%, inflow of $167 million - Ganfeng Lithium (01772.HK): +0.093%, inflow of $134 million - Dongfeng Motor Group (00489.HK): +0.092%, inflow of $133.6 million [2] - Expected outflows for stocks with decreased weights include: - Tencent (00700.HK): -0.231%, outflow of $334 million - Alibaba-W (09988.HK): -0.137%, outflow of $198 million - Kuaishou-W (01024.HK): -0.061%, outflow of $88.1 million - China Everbright Bank (06818.HK): -0.047%, outflow of $68.1 million [2][3]

Core Insights - MSCI announced the results of its index review for November 2025, with adjustments effective after the market close on November 24 [1] - Kintor Pharmaceutical (stock code: 2171.HK) has been added to the MSCI Global Small Cap Index, transitioning from the MSCI Hong Kong Small Cap Index to the China region index [1] - Inclusion in MSCI indices is seen as a signal of recognition by global capital markets, potentially attracting passive fund allocations and enhancing liquidity for the company [1] Company Overview - Kintor Pharmaceutical is a leading player in the CGT (Cell and Gene Therapy) sector in China, focusing on innovative CAR-T cell therapies for treating hematological malignancies and solid tumors [1] - The company aims to address key challenges in the CAR-T field, including tackling hard-to-treat tumors and reducing treatment costs to make therapies more accessible to the public [1] - The inclusion in the MSCI Global Small Cap Index is expected to increase global investor attention on Kintor Pharmaceutical, further enhancing its stock liquidity and market valuation [1]

Core Viewpoint - Gilead Sciences-B (01672) saw a stock increase of over 7%, currently trading at 10.11 HKD, following its inclusion in the MSCI Global Small Cap Index, effective after market close on November 24 [1] Group 1: Stock Performance - Gilead Sciences-B's stock rose by 6.98%, with a trading volume of 21.57 million HKD [1] Group 2: MSCI Inclusion - On November 6, MSCI announced the results of its November index review, which included Gilead Sciences-B in the MSCI Global Small Cap Index [1] Group 3: Clinical Research Updates - Gilead Sciences-B presented multiple reports at the 2025 ObesityWeek in Atlanta, Georgia, including a complete analysis of the ASC30 oral tablet Phase Ib study [1] - The ASC30 oral tablet study showed an average weight loss of up to 6.5% after placebo adjustment, demonstrating good safety and tolerability with only mild to moderate gastrointestinal adverse events [1] - The apparent half-lives of the ASC30 injection were 46 days and 75 days, supporting monthly and quarterly dosing regimens [1]

Group 1 - MSCI announced changes to its indices on November 6, including the addition of 17 A-shares and the removal of 16 A-shares, effective after the market close on November 24 [1] - Newly added A-shares include companies such as Qianli Technology, Dongyangguang, and Changchuan Technology, while removed A-shares include names like Zhongzhi Co., Bertli, and Dong'a Ejiao [1] - In addition to A-shares, the MSCI China Index also added 9 Hong Kong stocks, including Zijin Mining International and GF Securities, while removing 4 stocks such as Beikong Water Group and China Everbright Bank [1] Group 2 - The largest newly added stocks in the MSCI Global Standard Index include CoreWeave, Nebius Group, and Insmed, while the largest in the MSCI Emerging Markets Index are Barito Renewables Energy, Zijin Mining International, and GF Securities [2] - MSCI conducts four routine adjustments to its indices annually, with the May and November adjustments being more significant compared to the smaller adjustments in February and August [2]

Group 1 - MSCI announced the results of its November index review, which includes the addition of 17 new A-shares and the removal of 16 A-shares [2][3] - The newly added A-shares include companies such as Qianli Technology, Dongyangguang, and Changchuan Technology, while the removed A-shares include companies like Zhongzhi Co., Bertley, and Dong'a Ejiao [1][3] - The adjustments will take effect after the market closes on November 24 [2] Group 2 - In addition to A-shares, MSCI also included 9 new Hong Kong stocks in its indices, such as Zijin Mining International and GF Securities, while removing 4 Hong Kong stocks [3][4] - The largest new additions to the MSCI Global Standard Index include companies like CoreWeave, Nebius Group, and Insmed, indicating a focus on sectors like cloud services and biopharmaceuticals [4] - MSCI conducts four routine adjustments to its indices each year, with the November review being one of the two major semi-annual assessments [5]

Group 1 - MSCI announced the results of its index review for November 2025, with 69 stocks added and 64 stocks removed from the global standard index, effective after market close on November 24 [1] - The three largest securities added to the MSCI global index by market capitalization are CoreWeave, Nebius Group, and Insmed [1] - The three largest securities added to the MSCI emerging markets index are Barito Renewables Energy, Zijin Mining International, and GF Securities H-shares [1] Group 2 - In the MSCI China index, 26 Chinese stocks were added while 20 were removed, including resource stocks and technology companies such as China Gold International and Ganfeng Lithium [2] - The stocks removed from the MSCI China index include Haige Communications, Dong-E E-Jiao, and HLA Corp [2][4] - The MSCI China A-share index added 17 stocks and removed 16, with notable additions including Qianli Technology and Huahong Semiconductor [6] Group 3 - The MSCI China onshore A-share index added 18 stocks and removed 24, with new additions like Baiwei Storage and Shengtun Mining [6] - The MSCI China index serves as a key benchmark for global investors for asset allocation and investment analysis, impacting passive fund tracking [8] - The adjustments in MSCI indices will lead to increased fund allocation to newly added companies and forced selling of removed companies by index funds [9] Group 4 - Recent insights from foreign investment firms indicate a preference for emerging markets over developed markets, with a positive outlook on the Chinese stock market due to anticipated consumer stimulus measures [9][10] - Despite mixed views on the Chinese stock market, there is recognition of significant growth potential within the second-largest economy [10]